Time course of disease characteristics in patients with severe allergic asthma starting treatment with omalizumab.

Popov, Todor A; Hristova, Diana; Kralimarkova, Tanya Z; Mustakov, Tihomir B; Christoff, George H

Popov, Todor A; Hristova, Diana; Kralimarkova, Tanya Z; Mustakov, Tihomir B; Christoff, George H.

Afiliación

Popov TA; University Hospital Sv Ivan Rilski, Clinic of Occupational DIseases, Sofia, Bulgaria. Electronic address: tedpop@rtb-mul.com.
Hristova D; Alexander's University Hospital, Clinic of Allergology, Sofia, Bulgaria.
Kralimarkova TZ; Alexander's University Hospital, Clinic of Allergology, Sofia, Bulgaria.
Mustakov TB; Alexander's University Hospital, Clinic of Allergology, Sofia, Bulgaria.
Christoff GH; Faculty of Public Health, Medical University-Sofia, Sofia, Bulgaria.

Ann Allergy Asthma Immunol ; 128(4): 468-469, 2022 04.

Article en En | MEDLINE | ID: mdl-35085820

Asunto(s)

Antiasmáticos; Asma; Hipersensibilidad; Antiasmáticos/uso terapéutico; Asma/tratamiento farmacológico; Humanos; Omalizumab/uso terapéutico; Resultado del Tratamiento

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Asma / Antiasmáticos / Hipersensibilidad Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Ann Allergy Asthma Immunol Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2022 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google